Dr. Marco Borgogno is a team leader in discovery chemistry and a board member at IAMA Therapeutics. Marco leads the chemistry team towards the early and late-stage development of the new molecular entities of IAMA Therapeutics’ pipeline to treat neurodevelopmental disorders. Marco has a strong background in medicinal and organic chemistry applied to early drug discovery and more advanced drug development phases, primarily focusing on CNS disorders and cancer. He joined IAMA Therapeutics after an extensive postdoctoral experience in medicinal chemistry at the Italian Institute of Technology (IIT). During this time, he was responsible for different medicinal chemistry programs targeting cation-chloride cotransporters and delivered several lead compounds to treat different neurological disorders. During his Ph.D., he discovered and optimized novel selective NKCC1 inhibitors to treat neurodevelopmental disorders and successfully delivered one lead compound that entered advanced preclinical studies to treat autism. Marco is co-author of several research papers and abstracts and co-inventor of one patent application.
Marco holds an M.S. in Medical and Pharmaceutical Biotechnology from the University of Genova and a Ph.D. in biotechnological and pharmaceutical sciences from the University of Bologna.